Literature DB >> 32021603

Deep Phenotyping of Development, Communication and Behaviour in Phelan-McDermid Syndrome.

Gilles Droogmans1, Ann Swillen1,2, Griet Van Buggenhout1,2.   

Abstract

Phelan-McDermid syndrome (PMS; also referred to as 22q13.3 deletion syndrome) is a congenital condition due to a microdeletion in the SHANK3 gene. Cognitive and communicative deficits as well as behaviour in the autism spectrum are often noticed in affected individuals. The aim of the present study was to obtain a detailed phenotype of the development, communication, and behaviour of 15 individuals with PMS by using both quantitative (questionnaires) and qualitative methods (interviews and observations). In addition, data from the patients' medical records were included. In a subgroup of participants (n = 5), data from a previous study were incorporated to enable a comparison over 2 points in time (longitudinal course). Results indicate a severe to profound level of intellectual disability in all participants, impaired adaptive behaviour, a low level of speech and language, a high incidence of features of autism spectrum disorder (ASD), and a high sensory threshold. Younger individuals (age <18 years) exhibited more challenging behaviour and features of ASD. In older individuals with PMS, a regression across many developmental and adaptive domains was frequently reported and observed. We did not find a relation between the deletion size and the severity of the phenotype. Implications of the findings and recommendations for clinical practice and future research are discussed.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  22q13.3 Deletion syndrome; Autism; Behaviour; Communication; Development; Genotype-phenotype correlation; Intellectual disability; Phelan-McDermid syndrome; Regression

Year:  2019        PMID: 32021603      PMCID: PMC6995976          DOI: 10.1159/000503840

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  25 in total

1.  Chromosome 22q13.3 deletion syndrome with a de novo interstitial 22q13.3 cryptic deletion disrupting SHANK3.

Authors:  A Delahaye; A Toutain; A Aboura; C Dupont; A C Tabet; B Benzacken; J Elion; A Verloes; E Pipiras; S Drunat
Journal:  Eur J Med Genet       Date:  2009-05-18       Impact factor: 2.708

2.  22q13 deletion syndrome.

Authors:  M C Phelan; R C Rogers; R A Saul; G A Stapleton; K Sweet; H McDermid; S R Shaw; J Claytor; J Willis; D P Kelly
Journal:  Am J Med Genet       Date:  2001-06-15

3.  The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome).

Authors:  K Phelan; H E McDermid
Journal:  Mol Syndromol       Date:  2011-11-22

Review 4.  22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay.

Authors:  Kristina Cusmano-Ozog; Melanie A Manning; H Eugene Hoyme
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-11-15       Impact factor: 3.908

Review 5.  22q13 deletion syndrome: an update and review for the primary pediatrician.

Authors:  Joaquim M Havens; Jeannie Visootsak; Mary C Phelan; John M Graham
Journal:  Clin Pediatr (Phila)       Date:  2004 Jan-Feb       Impact factor: 1.168

Review 6.  The sensations of everyday life: empirical, theoretical, and pragmatic considerations.

Authors:  W Dunn
Journal:  Am J Occup Ther       Date:  2001 Nov-Dec

Review 7.  ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease.

Authors:  Tobias M Boeckers; Jürgen Bockmann; Michael R Kreutz; Eckart D Gundelfinger
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

8.  Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports.

Authors:  Sylvie Serret; Susanne Thümmler; Emmanuelle Dor; Stephanie Vesperini; Andreia Santos; Florence Askenazy
Journal:  BMC Psychiatry       Date:  2015-05-07       Impact factor: 3.630

9.  Interstitial 22q13 deletions not involving SHANK3 gene: a new contiguous gene syndrome.

Authors:  Vittoria Disciglio; Caterina Lo Rizzo; Maria Antonietta Mencarelli; Mafalda Mucciolo; Annabella Marozza; Chiara Di Marco; Antonio Massarelli; Valentina Canocchi; Margherita Baldassarri; Enea Ndoni; Elisa Frullanti; Sonia Amabile; Britt Marie Anderlid; Kay Metcalfe; Cédric Le Caignec; Albert David; Alan Fryer; Odile Boute; Andrieux Joris; Donatella Greco; Vanna Pecile; Roberta Battini; Antonio Novelli; Marco Fichera; Corrado Romano; Francesca Mari; Alessandra Renieri
Journal:  Am J Med Genet A       Date:  2014-04-03       Impact factor: 2.802

10.  Autism spectrum disorder in Phelan-McDermid syndrome: initial characterization and genotype-phenotype correlations.

Authors:  Lindsay M Oberman; Luigi Boccuto; Lauren Cascio; Sara Sarasua; Walter E Kaufmann
Journal:  Orphanet J Rare Dis       Date:  2015-08-27       Impact factor: 4.123

View more
  9 in total

1.  Descriptive Analysis of Adaptive Behavior in Phelan-McDermid Syndrome and Autism Spectrum Disorder.

Authors:  Sergio Serrada-Tejeda; Rosa M Martínez-Piédrola; Nuria Máximo-Bocanegra; Patricia Sánchez-Herrera-Baeza; Marta Pérez-de-Heredia-Torres
Journal:  Front Neurosci       Date:  2022-07-04       Impact factor: 5.152

2.  Strong evidence for genotype-phenotype correlations in Phelan-McDermid syndrome: results from the developmental synaptopathies consortium.

Authors:  Tess Levy; Jennifer H Foss-Feig; Catalina Betancur; Paige M Siper; Maria Del Pilar Trelles-Thorne; Danielle Halpern; Yitzchak Frank; Reymundo Lozano; Christina Layton; Bari Britvan; Jonathan A Bernstein; Joseph D Buxbaum; Elizabeth Berry-Kravis; Craig M Powell; Siddharth Srivastava; Mustafa Sahin; Latha Soorya; Audrey Thurm; Alexander Kolevzon
Journal:  Hum Mol Genet       Date:  2022-02-21       Impact factor: 5.121

3.  Case study: organizing outpatient pharmacological treatment of bipolar disorder in autism, intellectual disability and Phelan-McDermid syndrome (22q13.3 deletion syndrome).

Authors:  Anne Langseth Rysstad; Arvid Nikolai Kildahl; Jon Olav Skavhaug; Monica Stolen Dønnum; Sissel Berge Helverschou
Journal:  Int J Dev Disabil       Date:  2020-06-09

4.  Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report.

Authors:  Sarah Jesse; Jan Philipp Delling; Michael Schön; Tobias M Boeckers; Albert Ludolph; Makbule Senel
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 5.  Electrophysiological and Behavioral Evidence for Hyper- and Hyposensitivity in Rare Genetic Syndromes Associated with Autism.

Authors:  Anastasia Neklyudova; Kirill Smirnov; Anna Rebreikina; Olga Martynova; Olga Sysoeva
Journal:  Genes (Basel)       Date:  2022-04-11       Impact factor: 4.141

6.  Sensory processing and adaptive behavior in Phelan-McDermid syndrome: a cross-sectional study.

Authors:  Sergio Serrada-Tejeda; María-Luz Cuadrado; Rosa Mª Martínez-Piédrola; Nuria Máximo-Bocanegra; Patricia Sánchez-Herrera-Baeza; Lucía Rocío Camacho-Montaño; Marta Pérez-de-Heredia-Torres
Journal:  Eur J Pediatr       Date:  2022-07-15       Impact factor: 3.860

7.  Phelan-McDermid Syndrome in Pediatric Patients With Novel Mutations: Genetic and Phenotypic Analyses.

Authors:  Liang Chen; Zhi-Ye Yao; Xiangtao Wu; Shao-Ru He; Yu-Mei Liu; Xue-Yan Wang; De-Zhi Cao; Xing-Kun Yang; Jian-Bo Zhao; Zi Ren; Hong Li; Zheng Pei; Hong-Ke Ding; Zhi-Chun Feng
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

8.  Reduced brain volume and white matter alterations in Shank3-deficient rats.

Authors:  Carla E M Golden; Victoria X Wang; Hala Harony-Nicolas; Patrick R Hof; Joseph D Buxbaum
Journal:  Autism Res       Date:  2021-07-27       Impact factor: 4.633

9.  Sensory Reactivity Phenotype in Phelan-McDermid Syndrome Is Distinct from Idiopathic ASD.

Authors:  Teresa Tavassoli; Christina Layton; Tess Levy; Mikaela Rowe; Julia George-Jones; Jessica Zweifach; Stacey Lurie; Joseph D Buxbaum; Alexander Kolevzon; Paige M Siper
Journal:  Genes (Basel)       Date:  2021-06-26       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.